{"schema_version":"1.0","type":"article","title":"OBI–Novartis: Inside the ADC License","url":"https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform-en.md","lang":"en","date":"2026-11-15","publish_at":"2026-11-15T08:00:00+08:00","updated_at":"2026-11-15","category":"商業分析系列","topic":"BD / 授權","tags":["浩鼎","諾華","ADC","平台授權"],"summary":"The OBI–Novartis ADC agreement separates a $30m upfront from conditional milestones, with exclusivity defined by selected payload classes and key funding and retained-rights terms undisclosed.","key_points":["$30m is an agreed upfront, not confirmed cash received; total potential value exceeds $2bn.","Exclusivity covers selected Novartis payload classes; additional target restrictions are undisclosed.","Expansion pricing, research funding, retained rights and termination provisions are undisclosed."],"facts":[],"sections":["01 | Separate the upfront commitment from contingent value","02 | The disclosed exclusive field is defined by payload classes","03 | Compare fields, options and work before comparing price","04 | What the upfront means for a Taiwan platform business","05 | Five questions the disclosures leave open","References"],"references":[{"title":"[2] 2025年合併財務報告，頁8、10、13","source":"OBI Pharma","date":"2026-03-09","url":"https://www.obipharma.com/investor-overview/financial-report/"},{"title":"[5] Technology Platform","source":"OBI Pharma","date":"","url":"https://www.obipharma.com/what-we-do/technology-platform/"},{"title":"[6] Pipeline Overview","source":"OBI Pharma","date":"","url":"https://www.obipharma.com/what-we-do/pipeline-overview/"},{"title":"[11] Chugai and Araris enter license agreement","source":"Chugai","date":"2026-02-10","url":"https://www.chugai-pharm.co.jp/english/news/detail/20260210173000_1227.html"},{"title":"[12] Global collaboration with Genentech on DUPAC","source":"DualityBio","date":"2026-08-28","url":"https://en.dualitybiologics.com/news/614.html"},{"title":"[13] OBI decided to terminate OBI-822 Phase 3 study","source":"OBI Pharma","date":"2025-04-23","url":"https://www.obipharma.com/announcement/obi-decided-to-terminate-obi-822-phase-3-study-based-on-dsmbs-recommendation-and-to-redirect-resources-towards-adcs-development/"},{"title":"[16] 台灣浩鼎與諾華簽署合作暨授權協議，瀏覽器完整正文","source":"台灣浩鼎","date":"2026-11-13","url":"https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/"},{"title":"[17] 新臺幣／美元銀行間收盤匯率32.838","source":"中央銀行","date":"2026-11-13","url":"https://www.cbc.gov.tw/tw/mp-1.html"},{"title":"[18] 115年第3季合併資產負債表、綜合損益表及現金流量表","source":"MOPS／4174","date":"","url":"https://mopsov.twse.com.tw/mops/web/t164sb03"},{"title":"[19] 公告本公司召開重大訊息記者會新聞稿內容，序號3、17:17:30","source":"MOPS／4174","date":"2026-11-13","url":"https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&off=1&TYPEK=otc&co_id=4174&spoke_date=20261113&spoke_time=171730&seq_no=3"},{"title":"[20] Collaboration and License Agreement with Novartis，英文完整正文","source":"OBI Pharma","date":"2026-11-13","url":"https://www.obipharma.com/news/signs-collaboration-and-license-agreement-with-novartis/"},{"title":"[21] Boehringer Ingelheim broadens oncology portfolio，Synaffix公司原始發布稿","source":"Synaffix B.V.／PR Newswire","date":"2025-01-09","url":"https://www.prnewswire.com/news-releases/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-synaffixs-adc-technology-302346940.html"},{"title":"This article provides industry and company analysis and does not constitute investment or medical advice.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | Upfront commitment and conditional payments","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform-en/figure-01.png"},{"alt":"Figure 2 | Glycan-based attachment connects payloads to antibodies","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform-en/figure-02.png"},{"alt":"Figure 3 | Platform deals use different payment denominators","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform-en/figure-03.png"},{"alt":"Figure 4 | Internal programs and platform collaboration coexist","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-15）。OBI–Novartis: Inside the ADC License。https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “$30m is an agreed upfront, not confirmed cash received”?","a":"$30m is an agreed upfront, not confirmed cash received; total potential value exceeds $2bn."},{"q":"What are the key developments in “Exclusivity covers selected Novartis payload classes”?","a":"Exclusivity covers selected Novartis payload classes; additional target restrictions are undisclosed."},{"q":"What are the key developments in “Expansion pricing, research funding, retained rights and termination provisions are undisclosed”?","a":"Expansion pricing, research funding, retained rights and termination provisions are undisclosed."}]}